C O Bingham

Summary

Affiliation: Johns Hopkins University
Country: USA

Publications

  1. ncbi Treatment, management, and monitoring of established rheumatoid arthritis
    Clifton O Bingham
    Division of Rheumatology and Allergy, The Johns Hopkins University, Baltimore, MD, USA
    J Fam Pract 56:S1-7; quiz S8. 2007
  2. ncbi Periodontal disease and rheumatoid arthritis: the evidence accumulates for complex pathobiologic interactions
    Clifton O Bingham
    Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA
    Curr Opin Rheumatol 25:345-53. 2013
  3. ncbi Myocardial citrullination in rheumatoid arthritis: a correlative histopathologic study
    Jon T Giles
    Division of Rheumatology, Columbia University, College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032 USA
    Arthritis Res Ther 14:R39. 2012
  4. ncbi MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a Phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments
    Heleen Scheerens
    Genentech Research and Early Development, 1 DNA Way, South San Francisco, CA 94080, USA
    Arthritis Res Ther 13:R177. 2011
  5. ncbi Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and placebo
    Clifton O Bingham
    Division of Rheumatology, Johns Hopkins University, Baltimore, MD 21224, USA
    Rheumatology (Oxford) 48:1122-7. 2009
  6. ncbi Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies
    C O Bingham
    Johns Hopkins University Baltimore, MD, USA
    Rheumatology (Oxford) 46:496-507. 2007
  7. ncbi Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis st
    Clifton O Bingham
    Division of Rheumatology, Johns Hopkins University, 5200 Eastern Avenue, Mason F Lord Building, Center Tower, Room 404, Baltimore, MD 21224, USA
    Arthritis Rheum 54:3494-507. 2006
  8. ncbi Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study
    Clifton O Bingham
    Johns Hopkins University, Baltimore, MD 21224, USA
    Curr Med Res Opin 25:1131-42. 2009
  9. ncbi Emerging therapeutics for rheumatoid arthritis
    Clifton O Bingham
    John Hopkins University, Baltimore, MD, USA
    Bull NYU Hosp Jt Dis 66:210-5. 2008
  10. ncbi Immunomodulatory approaches to the management of chronic urticaria: an immune-mediated inflammatory disease
    Clifton O Bingham
    Divisions of Rheumatology and Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University, Baltimore, MD 21224, USA
    Curr Allergy Asthma Rep 8:278-87. 2008

Research Grants

  1. Periodontal Assessment in RA Study (PARAS)
    Clifton Bingham; Fiscal Year: 2007

Detail Information

Publications35

  1. ncbi Treatment, management, and monitoring of established rheumatoid arthritis
    Clifton O Bingham
    Division of Rheumatology and Allergy, The Johns Hopkins University, Baltimore, MD, USA
    J Fam Pract 56:S1-7; quiz S8. 2007
  2. ncbi Periodontal disease and rheumatoid arthritis: the evidence accumulates for complex pathobiologic interactions
    Clifton O Bingham
    Department of Medicine, Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA
    Curr Opin Rheumatol 25:345-53. 2013
    ..This review was conducted to focus on the recent clinical and translational research related to the associations between periodontal disease and rheumatoid arthritis...
  3. ncbi Myocardial citrullination in rheumatoid arthritis: a correlative histopathologic study
    Jon T Giles
    Division of Rheumatology, Columbia University, College of Physicians and Surgeons, 630 W 168th St, New York, NY 10032 USA
    Arthritis Res Ther 14:R39. 2012
    ..The aim of this study was to explore the presence and localization of myocardial citrullination in samples from rheumatoid arthritis (RA) patients compared to rheumatic and non-rheumatic disease control groups...
  4. ncbi MTRX1011A, a humanized anti-CD4 monoclonal antibody, in the treatment of patients with rheumatoid arthritis: a Phase I randomized, double-blind, placebo-controlled study incorporating pharmacodynamic biomarker assessments
    Heleen Scheerens
    Genentech Research and Early Development, 1 DNA Way, South San Francisco, CA 94080, USA
    Arthritis Res Ther 13:R177. 2011
    ....
  5. ncbi Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and placebo
    Clifton O Bingham
    Division of Rheumatology, Johns Hopkins University, Baltimore, MD 21224, USA
    Rheumatology (Oxford) 48:1122-7. 2009
    ..We evaluated whether early response to NSAIDs predicted later response, and when this was established...
  6. ncbi Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies
    C O Bingham
    Johns Hopkins University Baltimore, MD, USA
    Rheumatology (Oxford) 46:496-507. 2007
    ..To compare the efficacy of etoricoxib 30 mg with the generally maximum recommended dose of celecoxib, 200 mg, in the treatment of osteoarthritis (OA) in two identically designed studies...
  7. ncbi Risedronate decreases biochemical markers of cartilage degradation but does not decrease symptoms or slow radiographic progression in patients with medial compartment osteoarthritis of the knee: results of the two-year multinational knee osteoarthritis st
    Clifton O Bingham
    Division of Rheumatology, Johns Hopkins University, 5200 Eastern Avenue, Mason F Lord Building, Center Tower, Room 404, Baltimore, MD 21224, USA
    Arthritis Rheum 54:3494-507. 2006
    ....
  8. ncbi Effectiveness and safety of etanercept in subjects with RA who have failed infliximab therapy: 16-week, open-label, observational study
    Clifton O Bingham
    Johns Hopkins University, Baltimore, MD 21224, USA
    Curr Med Res Opin 25:1131-42. 2009
    ..The purpose of this study was to evaluate the effectiveness and safety of 50 mg etanercept weekly in subjects with RA who have failed infliximab therapy...
  9. ncbi Emerging therapeutics for rheumatoid arthritis
    Clifton O Bingham
    John Hopkins University, Baltimore, MD, USA
    Bull NYU Hosp Jt Dis 66:210-5. 2008
    ..This article provides a brief update of data from selected clinical trials in RA, highlighting efficacy, and mechanism-based safety concerns...
  10. ncbi Immunomodulatory approaches to the management of chronic urticaria: an immune-mediated inflammatory disease
    Clifton O Bingham
    Divisions of Rheumatology and Allergy and Clinical Immunology, Department of Medicine, Johns Hopkins University, Baltimore, MD 21224, USA
    Curr Allergy Asthma Rep 8:278-87. 2008
    ..Newer biologic and nonbiologic immunomodulatory agents approved for other indications and in clinical development provide potential options for this often severe disease...
  11. ncbi Developing a standardized definition for disease "flare" in rheumatoid arthritis (OMERACT 9 Special Interest Group)
    Clifton O Bingham
    Division of Rheumatology, Johns Hopkins University, 5200 Eastern Avenue, Mason Lord Center Tower, Room 404, Baltimore, MD 21224, USA
    J Rheumatol 36:2335-41. 2009
    ..This special interest group (SIG) was established to develop an evidence-based, consensus-driven standard definition of "flare" in rheumatoid arthritis (RA)...
  12. ncbi Responder analysis and correlation of outcome measures: pooled results from two identical studies comparing etoricoxib, celecoxib, and placebo in osteoarthritis
    C O Bingham
    Division of Rheumatology, Johns Hopkins University, Baltimore, MD 21224, USA
    Osteoarthritis Cartilage 16:1289-93. 2008
    ....
  13. ncbi Immunization responses in rheumatoid arthritis patients treated with rituximab: results from a controlled clinical trial
    Clifton O Bingham
    Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland 21224, USA
    Arthritis Rheum 62:64-74. 2010
    ....
  14. ncbi Predictors of response to cyclo-oxygenase-2 inhibitors in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib, and placebo
    Clifton O Bingham
    Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland 21224, USA
    Pain Med 12:352-61. 2011
    ..Nonsteroidal anti-inflammatory drug (NSAID) responses in osteoarthritis (OA) are highly variable, often requiring multiple medication changes. We sought to determine pre-randomization predictors of response to NSAIDs in OA...
  15. ncbi Identifying preliminary domains to detect and measure rheumatoid arthritis flares: report of the OMERACT 10 RA Flare Workshop
    Clifton O Bingham
    Johns Hopkins University, Baltimore, Maryland, USA
    J Rheumatol 38:1751-8. 2011
    ..While disease flares in rheumatoid arthritis (RA) are a recognized aspect of the disease process, there is limited formative research to describe them...
  16. ncbi Low molecular weight group IIA and group V phospholipase A(2) enzymes have different intracellular locations in mouse bone marrow-derived mast cells
    C O Bingham
    Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 274:31476-84. 1999
    ..The spatial segregation of group IIA PLA(2) and group V PLA(2) implies that these enzymes are not functionally redundant...
  17. ncbi Cytosolic phospholipase A2 is essential for both the immediate and the delayed phases of eicosanoid generation in mouse bone marrow-derived mast cells
    H Fujishima
    Department of Medicine, Harvard Medical School, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 96:4803-7. 1999
    ....
  18. ncbi Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis
    Daniel O Clegg
    Division of Rheumatology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA
    N Engl J Med 354:795-808. 2006
    ..The multicenter, double-blind, placebo- and celecoxib-controlled Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) evaluated their efficacy and safety as a treatment for knee pain from osteoarthritis...
  19. ncbi OARSI-OMERACT initiative: defining thresholds for symptomatic severity and structural changes in disease modifying osteoarthritis drug (DMOAD) clinical trials
    R L Manno
    Johns Hopkins University School of Medicine, Baltimore, MD 21224, USA
    Osteoarthritis Cartilage 20:93-101. 2012
    ..Our objective was to evaluate the prevalence of patients fulfilling different thresholds of sustained pain, reduced function, and X-ray change in existing DMOAD RCTs...
  20. ncbi A heparin-sensitive phospholipase A2 and prostaglandin endoperoxide synthase-2 are functionally linked in the delayed phase of prostaglandin D2 generation in mouse bone marrow-derived mast cells
    C O Bingham
    Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA
    J Biol Chem 271:25936-44. 1996
    ..Furthermore, this heparin-sensitive PLA2 likely represents a novel PLA2 or a new function for a known low molecular weight PLA2...
  21. ncbi Methotrexate combined with isoniazid treatment for latent tuberculosis is well tolerated in patients with rheumatoid arthritis: experience from an urban arthritis clinic
    A Mor
    Division of Rheumatology, Department of Medicine, New York University School of Medicine, Hospital for Joint Diseases, 301 East 17th Street, New York, NY 10003, USA
    Ann Rheum Dis 67:462-5. 2008
    ..The goal of this study was to investigate the toxicity of MTX and INH treatment in patients with RA before initiating TNF antagonists...
  22. ncbi A novel group of phospholipase A2s preferentially expressed in type 2 helper T cells
    I C Ho
    Department of Immunology and Infectious Diseases, Harvard School of Public Health, Division of Rheumatology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Biol Chem 276:18321-6. 2001
    ..These results suggest that group XII and group V PLA(2)s might participate in helper T cell immune response through release of immediate second signals and generation of downstream eicosanoids...
  23. ncbi Ethical issues in rheumatology clinical trials
    Jeremy Sugarman
    Bioethics and Medicine at Berman Institute of Bioethics, Johns Hopkins University, MD 21205, USA
    Nat Clin Pract Rheumatol 4:356-63. 2008
    ....
  24. ncbi Adiponectin is a mediator of the inverse association of adiposity with radiographic damage in rheumatoid arthritis
    Jon T Giles
    The Johns Hopkins University School of Medicine, Baltimore, Maryland
    Arthritis Rheum 61:1248-56. 2009
    ..Recent reports have suggested that increasing adiposity may protect against radiographic damage in rheumatoid arthritis (RA). We explored the role of serum adipokines (adiponectin, resistin, and leptin) in mediating this association...
  25. ncbi Catastrophizing and pain in arthritis, fibromyalgia, and other rheumatic diseases
    Robert R Edwards
    Dept of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, 600 N Wolfe Street, Meyer 1 101, Baltimore, MD 21287, USA
    Arthritis Rheum 55:325-32. 2006
    ....
  26. ncbi Assessing single joints in arthritis clinical trials
    Jon T Giles
    Division of Rheumatology, Johns Hopkins University, Baltimore, Maryland 21224, USA
    J Rheumatol 34:641-7. 2007
    ..At OMERACT 8, the group developed a research agenda to perform additional validation studies of clinical and functional indices, imaging, synovial histopathology, and soluble biomarkers...
  27. ncbi Remission in rheumatoid arthritis: wishful thinking or clinical reality?
    Carlos A Sesin
    Division of Rheumatology, NYU Hospital for Joint Diseases, New York, NY, USA
    Semin Arthritis Rheum 35:185-96. 2005
    ..To evaluate the prevalence of these outcomes with biologic therapy and traditional disease-modifying antirheumatic drugs (DMARD) regimens...
  28. ncbi Interleukin-3 regulates development of the 5-lipoxygenase/leukotriene C4 synthase pathway in mouse mast cells
    M Murakami
    Department of Medicine, Harvard Medical School, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    J Biol Chem 270:22653-6. 1995
    ....
  29. ncbi Development and clinical application of COX-2-selective inhibitors for the treatment of osteoarthritis and rheumatoid arthritis
    Clifton O Bingham
    New York University School of Medicine, and NYU Hospital for Joint Diseases, New York 10003, USA
    Cleve Clin J Med 69:SI5-12. 2002
    ....
  30. ncbi The pathogenesis of rheumatoid arthritis: pivotal cytokines involved in bone degradation and inflammation
    Clifton O Bingham
    New York University School of Medicine, Department of Rheumatology and Medicine, NYU Hospital for Joint Diseases, NY 10003, USA
    J Rheumatol Suppl 65:3-9. 2002
    ..However, in patients with active rheumatoid arthritis, blockade of either cytokine results in clinical improvement and less radiographic progression...
  31. ncbi Effect of cardiovascular comorbidities and concomitant aspirin use on selection of cyclooxygenase inhibitor among rheumatologists
    Jeffrey D Greenberg
    New York University Hospital for Joint Diseases, New York, New York, USA
    Arthritis Rheum 53:12-7. 2005
    ..To evaluate the effects of cardiovascular comorbidities and aspirin coprescription on cyclooxygenase (COX)-2 inhibitor (coxib) prescribing patterns among rheumatologists...
  32. ncbi Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals
    Jeffrey D Greenberg
    New York University Hospital for Joint Diseases, New York 10003, USA
    Arthritis Rheum 55:543-50. 2006
    ..To examine cyclooxygenase 2 inhibitor (coxib) utilization by rheumatologists for patients receiving nonsteroidal antiinflammatory drugs (NSAIDs) prior to the coxib market withdrawals...
  33. ncbi Resolution of inflammation: prostaglandin E2 dissociates nuclear trafficking of individual NF-kappaB subunits (p65, p50) in stimulated rheumatoid synovial fibroblasts
    Paul F Gomez
    Department of Rheumatology, Hospital for Joint Diseases and Department of Medicine, New York University School of Medicine, New York, NY 10003, USA
    J Immunol 175:6924-30. 2005
    ..Our data indicate that PGE2 may act to attenuate cytokine-induced inflammatory responses in RA synovial fibroblasts via regulation of the localization of specific NF-kappaB family dimers...
  34. ncbi Definitions and validation criteria for biomarkers and surrogate endpoints: development and testing of a quantitative hierarchical levels of evidence schema
    Marissa N Lassere
    Department of Rheumatology, St George Hospital, University of New South Wales, Sydney, Australia
    J Rheumatol 34:607-15. 2007
    ..Our objective was to review the literature on biomarkers and surrogates to develop a hierarchical schema that systematically evaluates and ranks the surrogacy status of biomarkers and surrogates; and to obtain feedback from stakeholders...
  35. ncbi Efficacy and safety of etanercept 50 mg twice a week in patients with rheumatoid arthritis who had a suboptimal response to etanercept 50 mg once a week: results of a multicenter, randomized, double-blind, active drug-controlled study
    Michael E Weinblatt
    Rheumatology and Immunology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Arthritis Rheum 58:1921-30. 2008
    ....

Research Grants1

  1. Periodontal Assessment in RA Study (PARAS)
    Clifton Bingham; Fiscal Year: 2007
    ....